Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8154101 | 0.88 | SLC6A7 (1.00) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL15703728 | 0.87 | ALDH1A1 (0.61) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL4323101 | 0.86 | ALDH1A1 (0.75) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL24288982 | 0.85 | ALDH1A1 (0.73) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL3578857 | 0.84 | SLC6A7 (0.78) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL4321986 | 0.84 | MEN1 (0.69) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL3587128 | 0.82 | SLC6A7 (0.78) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL14005561 | 0.81 | HPGD (0.72) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL4328329 | 0.81 | ALDH1A1 (0.72) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 | |
| SCHEMBL4321235 | 0.81 | ALDH1A1 (0.69) | ALDH1A1SLC6A7MAPK1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | ALDH1A1 3104/4885SLC6A7 234/4885MAPK1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.